| 货号 | 10008822-1mg |
| 描述 | Bortezomib is a dipeptide boronic acid derivative that reversibly inhibits the 20S proteasome (Ki = 0.6 nM).1 It binds the β5-subunit of the 20S proteasome and selectively inhibits chymotryptic activity.2,3,4 In part by blocking the degradation of tumor-suppressing and proapoptotic proteins, bortezomib drives cell cycle arrest and apoptosis in cancer cell lines and has applications in multiple myeloma and certain lymphomas, as well as other types of cancer.1,5 Proteasome inhibitors, including bortezomib, have potential in combination therapy with chemotherapy and radiation therapy against cancer.6,7,8,9 |
| 别名 | LDP-341;MG-341;MLN341;NSC 681239;PS-341;Velcade; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Ludwig, H.,Khayat, D.,Giaccone, G., et al. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104, 1794-1807 (2005). 2.Lightcap, E.S.,McCormack, T.A.,Pien, C.S., et al. Proteasome inhibition measurements: Clinical application. Clinical Chemistry 46(5), 673-683 (2000). 3.Adams, J. Development of the proteasome inhibitor PS-341. The Oncologist 7, 9-16 (2002). 4.Dou, Q.P., and Zonder, J.A. Overview of proteasome inhibitor-based anti-cancer therapies: Perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr. Cancer Drug Targets 14(6), 517-536 (2014). 5.Richardson, P.G.,Hideshima, T., and Anderson, K.C. Bortezomib (PS-341): A novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10(5), 361-369 (2003). 6.Mandl-Weber, S.,Meinel, F.G.,Jankowsky, R., et al. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. British Journal of Haematology 149, 518-528 (2010). 7.Minami, J.,Suzuki, R.,Mazitschek, R., et al. Histone deacetylase 3 (HDAC3) as a novel therapeutic target in multiple myeloma. Leukemia 28(3), 680-689 (2014). 8.Mato, A.R.,Feldman, T., and Goy, A. Proteasome inhibition and combination therapy for non-Hodgkin’s lymphoma: From bench to bedside. Oncologist 17(5), 694-707 (2012). 9.Al-Eisawi, Z.,Beale, P.,Chan, C., et al. Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models. J.Ovarian Res. 6(1), 78 (2013). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 384.2 |
| 分子式 | C19H25BN4O4 |
| CAS号 | 179324-69-7 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |